PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Building a better antipsychotic drug by treating schizophrenia's cause

In this week's Journal of Neuroscience, Pitt researchers report progress in understanding how drugs act on dopamine-producing neurons; could enable them to create more targeted treatments

2011-08-25
(Press-News.org) PITTSBURGH—The classic symptoms of schizophrenia – paranoia, hallucinations, the inability to function socially—can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

Now, researchers at Pitt have discovered that antipsychotic drugs work akin to a Rube Goldberg machine— that is, they suppress something that in turn suppresses the bad effects of schizophrenia, but not the exact cause itself. In a paper published in this week's Journal of Neuroscience, they say that pinpointing what's actually causing the problem could lead to better avenues of schizophrenia treatment that more directly and efficiently target the disease.

"In the past five years or so, we've really started to understand what may be going wrong with the schizophrenic brain," says Anthony Grace, Distinguished Professor of Neuroscience and professor of psychology in Pitt's School of Arts and Sciences and professor of psychiatry in the Pitt School of Medicine, who is senior author of the paper.

Schizophrenia is made up of three different types of symptoms. Positive symptoms, which are added onto a "normal" personality, include hallucinations and delusions, such as hearing voices, thinking people are after you, or thinking you're being targeted by aliens. Those are the classic symptoms of schizophrenia and the ones antipsychotic medications work on best. Grace says these are the symptoms most likely related to a neurotransmitter called dopamine.

The other two categories of symptoms are negative (what's missing from the normal personality—the ability to interact socially or hold down a job; some emotional flattening) and cognitive (the ability to think linearly or concentrate on one thing at a time). These two really aren't addressed well by antipsychotic drugs. "Blocking the dopamine system seems to fix classic hallucinations and delusions a whole lot better than it fixes the other problems," says Grace.

Grace has been studying the role dopamine plays in the schizophrenic brain since 1978. It's long been known that after several weeks of treatment with antipsychotic drugs, dopamine-producing neurons are inactivated. "It would suggest to us that in schizophrenia there is not too much dopamine, but rather the dopamine system is too responsive," says Grace.

Therefore, by inactivating the neurons, this overresponsivity should be able to be treated. "If there were just too much dopamine in the brain, one would expect the biggest treatment effect would be at the beginning and then it would diminish," Grace says.

But the actual effect is different—it builds over a couple days and then is constant; you don't get the tolerance you'd get with other drug treatments. This didn't fit with clinical observation. "Patients respond in the first few days, but we took weeks to see results in our normal animals," Grace says.

Grace's team developed a rat model that approximates some of the key features of schizophrenia. Rats exhibit the same symptoms one would expect from schizophrenia: sensory processing, cognition, and hyperresponsivity to amphetamines. When team members looked at this animal model and used these antipsychotic drugs, they found that what takes weeks to occur in a normal rat happens in a couple days in these schizophrenia-model rats. "It fits very well with the time course we see in human patients," says Grace.

What causes this to be the case? Grace hypothesizes that it's the schizophrenic brain's dopamine system working overtime. "Our recordings of dopamine neurons suggest that the dopamine system is turned up too high," says Grace. "That fits with human imaging studies in schizophrenics showing the dopamine system is overreacting."

Currently available antipsychotic drugs work by blocking dopamine receptors and stopping dopamine neurons from firing. "Using these drugs, we're fixing the overreactivity by causing the neurons to be inactive," says Grace. "It would be better to fix overreactivity by correcting what causes it.

"It's like fixing a car that's going too fast by taking out the engine instead of lifting your foot off the gas."

Getting Closer to the Source: The Hippocampus?

"What we're doing today, using antipsychotic drugs currently available, is putting a sort of patch several steps downstream from where we think the problem is," says Grace. "By using these animal models, we can start to work backwards to figure out why the drugs are having the effects they do. The next step to look further back and try to fix the problem at its source"

In the schizophrenic brain, it's not just the dopamine system that's hyperresponsive. The hippocampus is also hyperactive. Grace's research shows that this hippocampal hyperactivity probably causes the dopamine system to go into overdrive.

Grace recently published a paper in the journal Neuropsychopharmacology in which he looked at a novel compound that works on another neurotransmitter, called GABA.

"What we found in animal models and others have found postmortem in schizophrenic patients is that the hippocampus is lacking a certain type of GABA-ergic [GABA-producing] neuron that puts the brakes on the system," says Grace. "What we're trying to do is fix the GABA system that's broken and, by doing that, stabilize the system so the dopamine system responses are back to normal, so that we can actually fix what's wrong rather than trying to patch it several steps downstream.

"The dopaminergic system is easier because we have a good handle on what's going on," he adds. "Cognitive symptoms are more complex. We're trying to get a handle on how to approach those. Hopefully we can use some of this novel compound that we think is going to fix more of the symptoms and test in these domains."

After 30 years of studying dopamine and the schizophrenic brain, Grace is gratified to be getting an idea of just how antipsychotic drugs are addressing what we think is wrong with the dopamine system. It's not just simply blocking receptors, it's more complex and inactivates neurons that are hyprerresponsive.

"This is consistent with the hypothesis that the hippocampus is overdriving the system, and antipsychotics are just pushing it over the edge to shut it down," he says. "This gives us an idea of where to go to make a better antipsychotic drug."

### The coauthors of the paper are Kathryn Gill, a postdoctoral fellow in Pitt's Department of Neuroscience; and Pierangelo Cifelli, and Ornella Valenti, researchers who have since left the University to return to positions they hold in Italy.


ELSE PRESS RELEASES FROM THIS DATE:

No need to nag: study finds doctors' nutrition advice hits home early

2011-08-25
TORONTO, Ont., Aug 23, 2011— Hearing dietary advice twice is enough for patients to get the significant benefits of lower cholesterol, according to a new study led by doctors at St. Michael's Hospital and the University of Toronto. "We're seeing more and more people want to take their health into their own hands," said Dr. David Jenkins, the lead author of the study and director of the hospital's Risk Factor Modification Centre. Dr. Jenkins is also Canada's Research Chair in Nutrition and Metabolism at U of T's Department of Nutritional Sciences. Jenkins and his team ...

Construction Industry Has Most Traumatic Brain Injuries

2011-08-25
It may come as no surprise to construction workers, but a new study indicates that the construction industry has the highest number of traumatic brain injuries of all sectors of the U.S. workforce. For a variety of work-related injuries, construction workers may be able to make claims for workers' compensation benefits. The study, The Epidemiology of Fatal Occupational Traumatic Brain Injury in the U.S., analyzed data from the Census of Fatal Occupational Injury and the Current Population Survey, and it was performed by investigators from the National Institute for Occupational ...

Stay in ICU means fewer patients likely to renew prescriptions after discharge

2011-08-25
TORONTO, Ont., Aug. 23, 2011—Patients often do not renew prescriptions for their chronic diseases after they are released from hospital. The number is even lower if the patient spent time in an intensive care unit, according to a new study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Studies. "If you don't continue your medication after hospital, that can have consequences, such as hospital readmissions, visits to the emergency department and, in rare cases, death," said Dr. Chaim Bell, the lead researcher. Dr. Bell examined ...

Researchers uncover source of Haitian cholera outbreak

2011-08-25
Employing technology that reads the entire DNA code, researchers led by the Translational Genomics Research Institute and the Technical University of Denmark have pinpointed the source of a cholera outbreak in Haiti that killed more than 6,000 people and sickened 300,000. Paul Keim, Regents Professor of biology at Northern Arizona University and director of the TGen Pathogen Genomics Division, served as senior molecular biologist on the study, and NAU's Center for Microbial Genetics and Genomics also contributed. Using whole genome sequencing, which spells out the ...

California Among the Toughest States for Motorcyclists

2011-08-25
California Among the Toughest States for Motorcyclists Although motorcyclists in California enjoy great weather and beautiful scenery, the state is still among the most dangerous for bikers, according to a recent survey conducted by Progressive Insurance. According to Dan Kamionkowski, the company's Motorcycle Product Manager, California ranked 42nd in the country for motorcyclists because of the state's high gas prices, population density and motorcycle accident rates, as well as the poor road conditions throughout the state. Thanks to these factors, California is ...

Learning information the hard way may be best 'boot camp' for older brains

2011-08-25
Toronto, Canada – Canadian researchers have found the first evidence that older brains get more benefit than younger brains from learning information the hard way – via trial-and-error learning. The study was led by scientists at Baycrest's world-renowned Rotman Research Institute in Toronto and appears online Aug. 24, 2011 in the journal Psychology and Aging, ahead of the print edition. The finding will surprise professional educators and cognitive rehabilitation clinicians as it challenges a large body of published science which has shown that making mistakes while ...

Mechanism links substance abuse with vulnerability to depression

2011-08-25
It is well established that a mood disorder can increase an individual's risk for substance abuse, but there is also evidence that the converse is true; substance abuse can increase a person's vulnerability to stress-related illnesses. Now, a new study finds that repeated cocaine use increases the severity of depressive-like responses in a mouse model of depression and identifies a mechanism that underlies this cocaine-induced vulnerability. The research, published by Cell Press in the August 25 issue of the journal Neuron, may guide development of new treatments for mood ...

'Time cells' bridge the gap in memories of event sequences

2011-08-25
The hippocampus is a brain structure that plays a major role in the process of memory formation. It is not entirely clear how the hippocampus manages to string together events that are part of the same experience but are separated by "empty" periods of time. Now, new research published by Cell Press in the August 25 issue of the journal Neuron finds that there are neurons in the hippocampus that encode every sequential moment in a series of events that compose a discrete experience. "The hippocampus is critical for remembering the flow of events in distinct experiences ...

VLT looks into the eyes of the virgin

VLT looks into the eyes of the virgin
2011-08-25
The Eyes are about 50 million light-years away in the constellation of Virgo (The Virgin) and are some 100 000 light-years apart. The nickname comes from the apparent similarity between the cores of this pair of galaxies -- two white ovals that resemble a pair of eyes glowing in the dark when seen in a moderate-sized telescope. But although the centres of these two galaxies look similar, their outskirts could not be more different. The galaxy in the lower right, known as NGC 4435, is compact and seems to be almost devoid of gas and dust. In contrast, in the large galaxy ...

New York Civil rights Lawyer Investigates Claim of Race Discrimination at the Princeton Club of New York

2011-08-25
A former payroll manager is suing the Princeton Club in a $10 million age discrimination and race discrimination lawsuit. As reported by the New York Daily News, 51-year-old Jo-Ann Garcia was forced out of job in favor of a younger, English-speaking employee by club management. She was fired in March after spending nearly 30 years working at the W. 43rd St. clubhouse. "Racial harassment or race discrimination in the workplace by anyone or against anyone is wrong and illegal," said New York civil rights violations lawyer David Perecman, founder of The ...

LAST 30 PRESS RELEASES:

Being physically active, even just a couple of days a week, may be key to better health

High-fat diet promote breast cancer metastasis in animal models

A router for photons

Nurses and AI collaborate to save lives, reduce hospital stays

Multi-resistance in bacteria predicted by AI model

Tinker Tots: A citizen science project to explore ethical dilemmas in embryo selection

Sensing sickness

Cost to build multifamily housing in California more than twice as high as in Texas

Program takes aim at drinking, unsafe sex, and sexual assault on college campuses

Inability to pay for healthcare reaches record high in U.S.

Science ‘storytelling’ urgently needed amid climate and biodiversity crisis

KAIST Develops Retinal Therapy to Restore Lost Vision​

Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response

Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid

Low LDL cholesterol levels linked to reduced risk of dementia

Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients

Almost one in ten people surveyed report having been harmed by the NHS in the last three years

Enhancing light control with complex frequency excitations

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

New insight into factors associated with a common disease among dogs and humans

Illuminating single atoms for sustainable propylene production

New study finds Rocky Mountain snow contamination

Study examines lactation in critically ill patients

UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award

Doubling down on metasurfaces

New Cedars-Sinai study shows how specialized diet can improve gut disorders

Making moves and hitting the breaks: Owl journeys surprise researchers in western Montana

PKU Scientists simulate the origin and evolution of the North Atlantic Oscillation

ICRAFT breakthrough: Unlocking A20’s dual role in cancer immunotherapy

How VR technology is changing the game for Alzheimer’s disease

[Press-News.org] Building a better antipsychotic drug by treating schizophrenia's cause
In this week's Journal of Neuroscience, Pitt researchers report progress in understanding how drugs act on dopamine-producing neurons; could enable them to create more targeted treatments